Scientists have made significant strides in harnessing the body's immune cells to treat liquid tumors, but solid tumors have proven more elusive. These tumors are difficult to access and often secrete signals that suppress immune cells. However, a recent study by Stanford Medicine researchers and collaborators has uncovered a promising new approach to cell therapy. They've discovered a method to transform natural killer cells into a specialized form that can effectively infiltrate and destroy solid tumors.
The research, led by John Sunwoo, MD, and his team, involved isolating natural killer cells from human blood donors and exposing them to specific cellular signals. They found that a crucial ingredient in this recipe was TGF-b, a signaling protein emitted by various cell types, including tumor cells. However, the amount and presentation of TGF-b were critical. Too little, and the cells remained active; too much, and they became inhibited and dysfunctional. The optimal approach involved exposing the cells to short-lived human epithelial tumor cells, which presented a fleeting amount of active TGF-b, leading to highly efficient killers.
This discovery has significant implications for cancer treatment. The researchers found that these supercharged natural killer cells could infiltrate tumor organoids and slow the growth of various solid tumors in mice. When combined with cetuximab, a monoclonal antibody treatment, the therapy suppressed tumors even more effectively and without apparent adverse effects. This combination therapy is now being tested in a Phase I clinical trial for patients with advanced squamous cell carcinoma.
One of the most exciting aspects of this approach is its potential for widespread use. Unlike many immunotherapies, which are personalized and costly, this therapy can be produced in bulk, frozen, and administered to any patient in need. Sunwoo envisions it as an 'off-the-shelf drug' that could make cell therapy more accessible.
The study also highlights the importance of understanding the behavior of tissue-resident natural killer cells. These cells, which reside in tissues like the skin and lungs, have been subject to contradictory research. Some studies suggest they are sluggish killers, while others indicate they are highly efficient. Sunwoo's research helps clarify this by identifying two distinct types of tissue-resident natural killer cells with different functions, depending on their environment.
In conclusion, this study represents a significant advancement in the field of cancer immunotherapy. By transforming natural killer cells into a specialized form that can effectively combat solid tumors, researchers have opened up new possibilities for treatment. The potential for an off-the-shelf therapy that can be widely accessible is particularly exciting, and the ongoing clinical trial will provide further insights into its effectiveness and safety.
